Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Kathleen M. Dungan MD, MPH Advisory Board

Richard E. Pratley MD Associate Editor

See All Experts

featured

Published in Diabetes

Journal Scan / Research · October 03, 2023

Impact of Attending Virtual Peer Groups on HbA1c and CGM Use in Adolescents and Young Adults With Type 1 Diabetes

Diabetes Technology & Therapeutics

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Laura Nally MD, FAAP

Diabetes Technology & Therapeutics

Virtual Peer Groups Reduce HbA1c and Increase Continuous Glucose Monitor Use in Adolescents and Young Adults with Type 1 Diabetes

Diabetes Technol. Ther. 2023 Sep 01;25(9)589-601, DI Bisno, MW Reid, EA Pyatak, J Flores Garcia, E Salcedo-Rodriguez, A Torres Sanchez, DS Fox, S Hiyari, JL Fogel, I Marshall, G Bachmann, JK Raymond

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Impact of Attending Virtual Peer Groups on HbA1c and CGM Use in Adolescents and Young Adults With Type 1 Diabetes

Additional Info

Virtual Peer Groups Reduce HbA1c and Increase Continuous Glucose Monitor Use in Adolescents and Young Adults with Type 1 Diabetes

Further Reading

Perinatal Outcomes in Patients With Early vs Late Gestational Diabetes Mellitus Treated Between 24 and 28 Weeks of Gestation

Association Between Bone Mineral Density and the Risk of Kidney Disease Progression in Patients With Type 1 Diabetes

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes — 2025

Role of Intermittent Fasting in Weight Management and Improving Metabolic Health

Consensus Considerations and Good Practice Points for the Use of CGM Systems in Hospital Settings

Weight Changes After Treatment With Semaglutide in Individuals With MASLD/MASH With or Without Type 2 Diabetes

Potential Off-Label Indication of Metformin for Ischaemic Stroke

GLP-1 Agonists Combined With GIP and/or GCG Agonists vs GLP-1 Agonists Alone for Weight Loss in Adults With Obesity Without Type 2 Diabetes

Effect of Long-Term Glycemic Burden on the Incidence of Diabetic Foot Ulcers

Weight Maintenance Using Cost-Effective Antiobesity Medications After 1 Year of GLP-1 Receptor Agonist Therapy

Trends in the Incidence of Young Adult–Onset Diabetes by Diabetes Type

Recently Updated